Skip to content

Regenxbio RGNX Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
Biogen logo
BiogenBIIB
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX

Other financials

Income statement

See full
Revenue$6.4M-92.8%
Gross profit$14.9M+35.7%
Operating income-$83.4M-787%
Net income-$90.1M-1,580%
EPS (diluted)-$1.72-1,533%

Balance sheet

See full
Cash & equivalents$15.2M-88.3%
Total debt$71.1M-11.0%
Total equity$21.1M-92.3%
Total assets$341.9M-30.4%

Cash flow

See full
Operating cash flow-$76.2M-327%
CapEx$1.2M+20.6%
Free cash flow-$77.4M-337%

Valuation

See full
Market cap$529.38M+24.6%
Enterprise value$585.22M+56.3%
P/S+3.3×

Profitability

See full
Gross margin59.7%+1.0pp
Operating margin-292.3%-613pp
Net margin-330.2%-588pp
FCF margin-269.2%-364pp

Returns & leverage

See full
Return on equity-196.4%-288pp
Debt / equity3.4×+3.1×
Current ratio2.6×-0.3×

Where this comes from

Reported directly by Regenxbio in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Regenxbio's operating lease right-of-use assets in other assets?
Regenxbio (RGNX) reported operating lease right-of-use assets in other assets of $45.54M in Q1 2026.
How has Regenxbio's operating lease right-of-use assets in other assets changed year-over-year?
Regenxbio's operating lease right-of-use assets in other assets decreased by 12.6% year-over-year, from $52.11M to $45.54M.
What is the long-term trend for Regenxbio's operating lease right-of-use assets in other assets?
Over 5 years (2020 to 2025), Regenxbio's operating lease right-of-use assets in other assets has grown at a -5.9% compound annual growth rate (CAGR), from $63.82M to $47.16M.